Related Experiment Video
Updated: May 1, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Risk of Complicated Upper Gastrointestinal Bleeding With Direct Oral Anticoagulants: An Asian Population-Based
Louis H S Lau1, Xiang Xiao2, Terry C F Yip2
1Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong; Institute of Digestive Diseases, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong.
Background & Aims:
Asian data on complicated upper gastrointestinal bleeding (UGIB) risks among direct oral anticoagulants (DOACs) are limited.
Methods:
An industry-independent, population-based, retrospective cohort study was performed in Hong Kong during 2011 to 2020. Subjects with new exposure to apixaban, dabigatran, edoxaban, or rivaroxaban were included. Baseline demographics, comorbidities, drugs, and laboratory results were balanced between DOACs by inverse probability of treatment weighting. Subjects were followed for 2 years with non-UGIB deaths considered as competing risks. Subdistribution hazard ratios (SHRs) were generated by Fine-Gray model. False discovery rate (FDR) was controlled by the Benjamini-Hochberg procedure for multiplicity. The primary outcome was complicated UGIB, defined as any UGIB-related death, or UGIB with a hemoglobin drop >2 g/dL; blood transfusion; emergent endoscopic procedure; radiological/surgical intervention; or rebleeding within 30 days.
Results:
A total of 58,229 subjects with new DOACs exposure were included (22,359 apixaban, 20,639 dabigatran, 2068 edoxaban, and 13,163 rivaroxaban). Compared with apixaban, edoxaban (SHR, 1.891; 95% confidence interval [CI], 1.091-3.275; P = .025; FDR-adjusted P = .039) and rivaroxaban (SHR, 1.441; 95% CI, 1.047-1.983; P = .026; FDR-adjusted P = .039), but not dabigatran, were associated with significantly higher risks of complicated UGIB, with a number-needed-to-harm of 244 for edoxaban and 427 for rivaroxaban, respectively. In subgroup analysis, apixaban was associated with a lower bleeding risk in subjects with age ≥80 years or estimated glomerular filtrate rate <60 mL/min/1.73 m2. Low-dose apixaban was associated with a lower bleeding risk among all low-dose DOACs.
Conclusions:
This Chinese population-based observational study demonstrated a lower 2-year risk of complicated UGIB in apixaban users compared with edoxaban and rivaroxaban, but not dabigatran, users among subjects without prior anticoagulant exposure.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...